Barclays Maintains Equal-Weight on Surgery Partners, Lowers Price Target to $14
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Andrew Mok maintains Surgery Partners (NASDAQ:SGRY) with a Equal-Weight and lowers the price target from $18 to $14.
Barclays analyst Andrew Mok maintains Surgery Partners (NASDAQ:SGRY) with a Equal-Weight and lowers the price target from $18 to $14.